Apomorphine intranasal - Nastech Pharmaceutical Company

Drug Profile

Apomorphine intranasal - Nastech Pharmaceutical Company

Latest Information Update: 14 Aug 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nastech Pharmaceutical Company
  • Class Analgesics; Antiparkinsonians; Aporphines; Erectile dysfunction therapies; Small molecules
  • Mechanism of Action Dopamine D2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Erectile dysfunction; Female sexual dysfunction

Most Recent Events

  • 14 Aug 2006 No development reported - Phase-II for Erectile dysfunction in USA (Intranasal)
  • 14 Aug 2006 No development reported - Phase-II for Female sexual dysfunction in USA (Intranasal)
  • 28 Apr 2004 Nastech has completed the phase II Maximum Tolerated Dose trial in Erectile dysfunction
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top